IntrinsicIntrinsic
← All summaries

Amesite Inc.

AMST
Financials & Chart →

Business Summary

Amesite Inc. is a technology company specializing in building and commercializing AI-powered solutions for the healthcare sector, with a primary focus on the post-acute care market. The company completed a strategic pivot in fiscal year 2025 from an education-centric model to one anchored in healthcare, driven by the perceived scale, complexity, and growth potential of this sector. The company operates through two product lines under its NurseMagic™ brand: a B2C (direct-to-practitioner) app and a B2B (enterprise) platform, both designed to address operational, compliance, and efficiency challenges for healthcare professionals and organizations. The company's Amesite Engage platform remains operational for its existing user base, but resources are not being dedicated to its growth .

The company's competitive positioning in the healthcare software market is at the intersection of several distinct segments: Electronic Medical Record (EMR) or Electronic Health Record (EHR) firms, mid-market and specialized vendors, AI-first entrants, and niche clinical tools. NurseMagic™ is designed to combine rapid deployment, practitioner-driven design, and robust compliance to meet evolving needs in post-acute care. The company believes its adoption rates and enterprise wins suggest its focus on real workflow impact, security, and regulatory alignment is resonating. However, the company faces substantial competition from existing players who have already overcome hurdles in the space .

Amesite's core business model revolves around generating revenue from a hosted platform of tightly integrated technology and services, primarily through monthly subscription fees. The company's performance obligation is to provide on-demand information and documentation solutions to its customers by leveraging its proprietary technology. Revenue is recognized ratably over the service period, generally one month. The primary customer segments are individual nurses and caregivers (B2C) and healthcare enterprises in post-acute settings (B2B), including home health, skilled nursing, hospice, assisted, and senior living centers. The B2C app offers a free version to lower adoption barriers and gather feedback, while the B2B solution emphasizes time savings, regulatory compliance, enhanced documentation accuracy, and improved staff efficiency and retention .

The NurseMagic™ B2C app connects directly with working nurses and caregivers, offering tools to reduce documentation time, simplify communication, and support daily workflow. This direct engagement allows for rapid feature refinement based on real-world feedback. For the fiscal year ended June 30, 2025, B2C sales accounted for 24% of total revenue, or $27,001 .

The NurseMagic™ B2B solution targets healthcare businesses in post-acute settings, such as home health, skilled nursing, hospice, and assisted and senior living centers. This platform aims to improve workflow efficiency, data security, and regulatory compliance. The B2C free version also serves as a tool for enterprise decision-makers to validate the impact of the app. For the fiscal year ended June 30, 2025, B2B sales accounted for 76% of total revenue, or $83,458 .

For the fiscal year ended June 30, 2025, Amesite reported total revenue of $110,459 . The company incurred a net loss of $3,617,086 . Basic and diluted loss per share was $(1.03) . Cash and cash equivalents totaled $2,333,418 , with restricted cash of $100,000 , bringing total cash, cash equivalents, and restricted cash to $2,433,418 . Total current liabilities were $358,596 . The company's accumulated earnings deficit was $(41,450,587) . Free cash flow is not explicitly stated, but net cash and cash equivalents used in operating activities was $(2,455,248) .

Comparing fiscal year 2025 to fiscal year 2024, total revenue decreased from $166,881 to $110,459 . This reduction was attributed to a strategic pivot away from larger, cash-upfront education deals that struggled with sustainable revenue, towards the NurseMagic™ app. Despite the overall revenue decline, the company experienced a turnaround in fiscal year 2025 as the NurseMagic™ customer base expanded. Net loss decreased from $(4,403,182) in fiscal year 2024 to $(3,617,086) in fiscal year 2025, a reduction of approximately $786,000 , primarily due to significant savings in general and administrative, technology and content development, and sales and marketing expenses, offset by an impairment charge. General and administrative expenses decreased by $430,401 , technology and content development expenses decreased by $383,174 , and sales and marketing expenses decreased by $218,885 .

During fiscal year 2025, Amesite completed its pivot to AI-powered solutions for the healthcare sector, launching NurseMagic™ in June 2024. Initial NurseMagic™ sales were recorded in the second quarter of fiscal year 2025. In February 2025, the product became available for online subscription, followed by its release on Google Play and the Apple App Store. In April 2025, NurseMagic™ achieved HIPAA compliance, and the company introduced NurseMagic™ Teams+, which contributed to accelerated customer adoption and revenue growth. The company also recognized an impairment loss of $90,869 related to capitalized software due to the decision to discontinue development of the higher education/professional learning app . In July 2025, the company introduced NurseMagic™ Enterprise, designed for larger-scale customers with features such as EMR integration, tailored compliance and billing documentation, and a patient census–based pricing model .

Business Outlook

Amesite Inc. is focused on expanding its NurseMagic™ offerings within the healthcare sector. The company introduced NurseMagic™ Enterprise in July 2025, targeting larger-scale customers. This enterprise solution includes features such as electronic medical record (EMR) integration, tailored compliance and billing documentation, and a patient census-based pricing model . This expansion aims to accelerate customer adoption and revenue growth, building on the traction gained by the B2C and B2B NurseMagic™ app offerings.

The company's operational outlook emphasizes continued fiscal discipline, launching and scaling innovative products while managing costs and prioritizing efficient resource allocation. This disciplined approach is intended to strengthen the potential for responsible and profitable growth. The company has made significant savings in general and administrative expenses, which decreased by $430,401 in fiscal year 2025 compared to fiscal year 2024, primarily due to reductions in employee payroll and Board of Directors compensation. Technology and content development expenses also decreased by $383,174 due to savings in employee payroll and lower capitalized software amortization. Sales and marketing expenses decreased by $218,885 due to lower marketing costs and employee payroll savings. The company will continue to capitalize significant software development costs, primarily internal payroll, payroll-related, and contractor costs, as it builds out and completes its technology platforms .

Regarding capital allocation, Amesite plans to generate cash by completing financing transactions, which may include offerings of common stock. The company closed a public offering on January 8, 2025, receiving approximately $3.08 million of cash proceeds, net of underwriting discounts, commissions, and other offering costs. The company does not anticipate declaring or paying any cash dividends for the foreseeable future, intending to retain all available funds and future earnings for the development, operation, and expansion of its business . Capital asset additions for capitalized technology and content development were $378,300 for the year ended June 30, 2025.

The company explicitly flags several structural headwinds and execution risks to its growth plan. These include the intense competitiveness of the healthcare software industry, with established platforms, agile mid-market firms, and numerous AI-first entrants, many of whom possess more resources and larger installed bases. There is no guarantee that healthcare organizations and individual practitioners will continue to adopt the NurseMagic™ platform, perceive sufficient differentiation or ROI, or retain their subscriptions over time. Market acceptance could be hindered by organizational inertia, integration challenges, the emergence of competing technologies, or negative perceptions of AI in clinical environments .

Geographic, regulatory, and macro factors are also identified as constraints. The healthcare industry is subject to extensive regulatory oversight at both federal and state levels, demanding strict standards for patient privacy, data security, clinical quality, and marketing practices, including HIPAA, the HITECH Act, and CMS rules. Evolving and overlapping data privacy laws at state, national, and international levels (such as GDPR) increase compliance complexity. Lapses in regulatory compliance by the company or its clients could result in penalties, legal liability, or restrictions on operations. General economic downturns, reductions in healthcare or IT spending, changes in regulatory or reimbursement environments, or disruptions to the company's workforce or supply chain could adversely impact sales, revenue, or execution capacity .

Risk Factors

Amesite Inc. faces substantial risks across several categories. Macroeconomic risks include general economic downturns, reductions in healthcare or IT spending, and changes in regulatory or reimbursement environments, which could adversely impact sales, revenue, or execution capacity. The company has a history of net losses, with approximately $3,617,000 for the year ended June 30, 2025, and negative cash flows from operating activities, raising substantial doubt about its ability to continue as a going concern. Competitive risks are significant, with established platforms, agile mid-market firms, and numerous AI-first entrants in the healthcare software industry, many possessing more resources and larger installed bases. Regulatory and compliance risks are high due to extensive federal and state oversight in healthcare, including HIPAA, the HITECH Act, CMS rules, and evolving AI-focused regulations; any failure to comply could lead to significant penalties, legal action, or operational restrictions. Operational risks include the reliance on the robustness, accuracy, and security of proprietary AI technologies, with bugs or performance issues potentially disrupting customer operations or eroding trust. Cybersecurity and data protection risks are inherent in managing health-related and personal information, with any breach potentially leading to severe financial, reputational, and legal consequences. The company also faces risks related to market penetration and adoption, as there is no guarantee that healthcare organizations and individual practitioners will continue to adopt its platform or perceive sufficient differentiation or ROI.

Management Priorities

Management's message to shareholders emphasizes a strategic pivot completed in fiscal year 2025, shifting from an education-centric model to AI-powered solutions for the healthcare sector, specifically focusing on the post-acute care market with the NurseMagic™ brand. The company highlights its disciplined approach to fiscal management, aiming to launch and scale innovative products while controlling costs and efficiently allocating resources to achieve responsible and profitable growth. Management believes it will have sufficient cash and cash equivalents to maintain planned operations for the next twelve months following the issuance of the financial statements, though acknowledges uncertainty in this forecast and that there are conditions raising substantial doubt about the company's ability to continue as a going concern. Key strategic priorities include expanding the NurseMagic™ offerings, as evidenced by the launch of NurseMagic™ Enterprise in July 2025, which features EMR integration and patient census-based pricing. Another priority is securing additional funding through financing transactions, potentially including common stock offerings, to support ongoing operations and growth. The company also stresses its commitment to maintaining full compliance with extensive healthcare regulations, such as HIPAA and the HITECH Act, as foundational to driving sustainable business performance and customer trust.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Competition
  3. [3] Item 1, Business — Our Sales and Marketing Motions; Item 7, MD&A — Revenue Recognition
  4. [4] Item 1, Business — Our Sales and Marketing Motions; Item 8, Note 2 — Revenue Recognition
  5. [5] Item 1, Business — Our Sales and Marketing Motions; Item 8, Note 2 — Revenue Recognition
  6. [6] Item 8, Statements of Operations — Net Revenue
  7. [7] Item 8, Statements of Operations — Net Loss
  8. [8] Item 8, Statements of Operations — Basic and diluted loss per share
  9. [9] Item 8, Balance Sheets — Cash and cash equivalents
  10. [10] Item 8, Balance Sheets — Restricted cash
  11. [11] Item 7, MD&A — Financial Position, Liquidity, and Capital Resources; Item 8, Note 1 — Liquidity and Going Concern
  12. [12] Item 8, Balance Sheets — Total current liabilities
  13. [13] Item 8, Balance Sheets — Accumulated earnings deficit
  14. [14] Item 8, Statements of Cash Flows — Net cash and cash equivalents used in operating activities
  15. [15] Item 8, Statements of Operations — Net Revenue
  16. [16] Item 8, Statements of Operations — Net Revenue
  17. [17] Item 8, Statements of Operations — Net Loss
  18. [18] Item 8, Statements of Operations — Net Loss
  19. [19] Item 7, MD&A — Net Loss
  20. [20] Item 7, MD&A — General and Administrative
  21. [21] Item 7, MD&A — Technology and Content Development
  22. [22] Item 7, MD&A — Sales and Marketing
  23. [23] Item 7, MD&A — Impairment Expense
  24. [24] Item 7, MD&A — Impairment Expense
  25. [25] Item 7, MD&A — Financial Position, Liquidity, and Capital Resources
  26. [26] Item 7, MD&A — Financial Position, Liquidity, and Capital Resources
  27. [27] Item 7, MD&A — General and Administrative
  28. [28] Item 7, MD&A — Technology and Content Development
  29. [29] Item 7, MD&A — Sales and Marketing
  30. [30] Item 7, MD&A — Capital Expenditures
  31. [31] Item 7, MD&A — Financial Position, Liquidity, and Capital Resources
  32. [32] Item 5, Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividends
  33. [33] Item 7, MD&A — Capital Expenditures
  34. [34] Item 1A, Risk Factors — Adoption, Market Penetration, and Growth Risks
  35. [35] Item 1A, Risk Factors — Compliance and Regulatory Risks; Item 1A, Risk Factors — General and Macroeconomic Risks
  36. [36] Item 1A, Risk Factors — General Risks

Analysis on 5/19/2026